Skip to main content
. Author manuscript; available in PMC: 2017 Nov 1.
Published in final edited form as: J Psychiatr Res. 2016 Jul 18;82:58–67. doi: 10.1016/j.jpsychires.2016.07.012

Figure 1. A subset of miRNAs validate as differentially expressed in AnCg of BP and/or MDD patients.

Figure 1

Vertical axis represents linear fold change in BP or MDD cohorts versus control patients (BP: n=8; MDD: n=15; Control: n=14). Expression levels were measured using Taqman-chemistry-based qPCR using individual assays. Three miRNAs (miR-132, 133a and 212) were dysregulated in BP, one (miR-184) was dysregulated in MDD and one miRNA—miR-34a, previously linked to schizophrenia—was dysregulated in both groups. All samples were run in technical triplicate with the snoRNA RNU48 serving as a reference control. (*: P < 0.05, #: P ≤ 0.10; error bars represent SEM.)